pharma · Acne Vulgaris · Pruritus · VYNE
VYNE Therapeutics
VYNE Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
- Founded
- 2003
- Employees
- 47
- Programs
- 30
- Drugs
- 16
- Patents
- 7
VYNE Therapeutics projects
6 ClinicalTrials.gov programs sponsored by VYNE Therapeutics.
VYNE Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
5 mg Serlopitant Tablets
VYNE Therapeutics
Pruritus
3 trials -
5mg Serlopitant Tablets
VYNE Therapeutics
Pruritus
2 trials -
FMX-101, 4% minocycline foam
VYNE Therapeutics
Acne Vulgaris
2 trials -
FMX101
VYNE Therapeutics
Acne Vulgaris
1 trial -
FMX103 1.5%
VYNE Therapeutics
Papulopustular Rosacea
1 trial -
FMX103 minocycline foam 1.5%
VYNE Therapeutics
Facial Papulopustular Rosacea
2 trials
Frequently asked questions
How many clinical projects does VYNE Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.